Literature DB >> 16417569

Copper (II) ions potently inhibit purified PrPres amplification.

Nicholas R Orem1, James C Geoghegan, Nathan R Deleault, Richard Kascsak, Surachai Supattapone.   

Abstract

The structural conversion of a host protein, PrP(C), into a protease-resistant isoform, PrPres, is the central event in the pathogenesis of infectious prion diseases. Purification of native PrP(C) molecules from hamster brain by either cation exchange or immobilized chelator chromatographic resins yielded preparations that supported efficient amplification of scrapie-induced PrPres in vitro. Using these purified preparations, we determined that in vitro PrPres amplification was inhibited by CuCl2 and ZnCl2 at IC50 concentrations of approximately 400 nm and 10 microM, respectively. In contrast, 100 microM MnCl2 did not directly inhibit PrPres amplification or block Cu2+-mediated inhibition. Additionally, the inhibition of PrPres amplification by Cu2+ ions could be reversed by addition of either neocuproine or imidazole. Cu2+ inhibited PrPres amplification in both the presence and absence of stimulatory polyanion molecules. These biochemical findings support the hypothesis that Cu2+ ions might regulate the pathogenesis of prion diseases in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417569     DOI: 10.1111/j.1471-4159.2006.03650.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  22 in total

1.  Immunodetection of glycophosphatidylinositol-anchored proteins following treatment with phospholipase C.

Authors:  Koren A Nishina; Surachai Supattapone
Journal:  Anal Biochem       Date:  2007-01-26       Impact factor: 3.365

2.  Formation of native prions from minimal components in vitro.

Authors:  Nathan R Deleault; Brent T Harris; Judy R Rees; Surachai Supattapone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

3.  Probing the role of PrP repeats in conformational conversion and amyloid assembly of chimeric yeast prions.

Authors:  Jijun Dong; Jesse D Bloom; Vladimir Goncharov; Madhuri Chattopadhyay; Glenn L Millhauser; David G Lynn; Thomas Scheibel; Susan Lindquist
Journal:  J Biol Chem       Date:  2007-09-24       Impact factor: 5.157

4.  Amplification of purified prions in vitro.

Authors:  Surachai Supattapone; Nathan R Deleault; Judy R Rees
Journal:  Methods Mol Biol       Date:  2008

Review 5.  Redox control of prion and disease pathogenesis.

Authors:  Neena Singh; Ajay Singh; Dola Das; Maradumane L Mohan
Journal:  Antioxid Redox Signal       Date:  2010-06-01       Impact factor: 8.401

6.  The Rich Electrochemistry and Redox Reactions of the Copper Sites in the Cellular Prion Protein.

Authors:  Feimeng Zhou; Glenn L Millhauser
Journal:  Coord Chem Rev       Date:  2012-05-04       Impact factor: 22.315

7.  Zinc drives a tertiary fold in the prion protein with familial disease mutation sites at the interface.

Authors:  Ann R Spevacek; Eric G B Evans; Jillian L Miller; Heidi C Meyer; Jeffrey G Pelton; Glenn L Millhauser
Journal:  Structure       Date:  2013-01-03       Impact factor: 5.006

Review 8.  Cofactor molecules: Essential partners for infectious prions.

Authors:  Surachai Supattapone
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-24       Impact factor: 3.622

Review 9.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

Review 10.  PrP overdrive: does inhibition of α-cleavage contribute to PrP(C) toxicity and prion disease?

Authors:  Alex J McDonald; Glenn L Millhauser
Journal:  Prion       Date:  2014-04-10       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.